Neurooncology

Toxicologic Pathology

Volumn 39, Issue 1, 2011, Pages 124-128

  Bradley, Alys E ^a   Keane, Kevin ^b  

^a CHARLES RIVER LABORATORIES   (United Kingdom)

^b Huntingdon Life Sciences New Jersey   (United States)

Author keywords

animal models; cancer; molecular pathology; nervous system; neuropathology; oncology; toxicity

Indexed keywords

ANIMAL; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; HEALTH CARE ORGANIZATION; HUMAN; METHODOLOGY; MOLECULAR PATHOLOGY; NERVOUS SYSTEM; NEUROLOGIC DISEASE; ORGANIZATION; PATHOLOGY; TOXICITY AND INTOXICATION;

ANIMALS; BRAIN NEOPLASMS; CONGRESSES AS TOPIC; HUMANS; MODELS, ANIMAL; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; NEUROTOXICITY SYNDROMES; PATHOLOGY, MOLECULAR; SOCIETIES, SCIENTIFIC;

EID: 79959519903     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310389477     Document Type: Review

References (20)

1. Brem S. S. Bierman P. J. Black P. Brem H. Chamberlain M. C. Chiocca E. A. DeAngelis L. M. Fenstermaker R. A. Friedman A. Gilbert M. R. Glass J. Grossman S. A. Heimberger A. B. Junck L. Linette G. P. Loeffler J. J. Maor M. H. Moots P. Mrugala M. Nabors L. B. Newton H. B. Olivi A. Portnow J. Prados M. Raizer J. J. Shrieve D. C. Sills A. K. Jr. (2008). Central nervous system cancers. J Natl Compr Canc 6, 456–504.
2. Brix A. E. Nyska A. Haseman J. K. Sells D. M. Jokinen M. P. Walker N. J. Cancer Genome Atlas Research Network. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455, 1061–1068.
3. Brix A. E. Nyska A. Haseman J. K. Sells D. M. Jokinen M. P. and Walker N. J. (2005). Incidences of selected lesions in control female Harlan Sprague-Dawley rats from two-year studies performed by the National Toxicology Program. Toxicol Pathol 33, 477–83.
4. Charles N. Holland E. C. (2010). The perivascular niche microenvironment in brain tumor progression. Cell Cycle. 9, 3012–21.
5. Chen R. Nishimura M. C. Bumbaca S. M. Kharbanda S. Forrest W. F. Kasman I. M. Greve J. M. Soriano R. H. Gilmour L. L. Rivers C. S. Modrusan Z. Nacu S. Guerrero S. Edgar K. A. Wallin J. J. Lamszus K. Westphal M. Heim S. James C. D. VandenBerg S. R. Costello J. F. Moorefield S. Cowdrey C. J. Prados M. and Phillips H. S. (2010). A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 17, 362–75.
6. Dang L. White D. W. Gross S. Bennett B. D. Bittinger M. A. Driggers E. M. Fantin V. R. Jang H. G. Jin S. Keenan M. C. Marks K. M. Prins R. M. Ward P. S. Yen K. E. Liau L. M. Rabinowitz J. D. Cantley L. C. Thompson C. B. Vander Heiden M. G. Su S. M. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462, 739–44.
7. Duran I. Raizer J. J. (2007). Low-grade gliomas: Management issues. Expert Rev Anticancer Ther. 7, S15–21.
8. Grimm S. Raizer J. J. (2008). Meningiomas. Curr Treat Options Neurol. 10, 315–20.
9. Han S. J. Yang I. Ahn B. J. Otero J. J. Tihan T. McDermott M. W. Berger M. S. Prados M. D. Parsa A. T. (2010). Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. Cancer. 116, 1358–66.
10. Harlan (Web information). (2008). Historical control data in RccHanTM:WIST rats. http://www.harlan.com/research_models_and_services/research_models_by_product_type/outbred_rats/wistar_hannover.hl
11. Huse J. T. Holland E. C. (2010). Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 10, 319–31.
12. Louis D. N. Ohgaki H. Wiestler O. D. Cavenee W. K. Burger P. C. Jouvet A. Scheithauer B. W. and Kleihues P. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97–109.
13. Momota H. Holland E. C. (2009). Mouse models of CNS embryonal tumors. Brain Tumor Pathol. 26, 43–50.
14. National Toxicology Program. (2004a). Historical control data in Fischer F344 rats. http://ntp.niehs.nih.gov/
15. National Toxicology Program. (2004b). Historical control data in B6C3F1 mice. http://ntp.niehs.nih.gov/
16. Parsons D. W. Jones S. Zhang X. Lin J. C. Leary R. J. Angenendt P. Mankoo P. Carter H. Siu I. M. Gallia G. L. Olivi A. McLendon R. Rasheed B. A. Keir S. Nikolskaya T. Nikolsky Y. Busam D. A. Tekleab H. Diaz L. A. Jr Hartigan J. Smith D. R. Strausberg R. L. Marie S. K. Shinjo S. M. Yan H. Riggins G. J. Bigner D. D. Karchin R. Papadopoulos N. Parmigiani G. Vogelstein B. Velculescu V. E. Kinzler K. W. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science. 321, 1807–12.
17. Phillips H. S. Kharbanda S. Chen R. Forrest W. F. Soriano R. H. Wu T. D. Misra A. Nigro J. M. Colman H. Soroceanu L. Williams P. M. Modrusan Z. Feuerstein B. G. Aldape K. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 9, 157–73.
18. Raizer J. J. Abrey L. E. Lassman A. B. Chang S. M. Lamborn K. R. Kuhn J. G. Yung W. K. Gilbert M. R. Aldape K. D. Wen P. Y. Fine H. A. Mehta M. Deangelis L. M. Lieberman F. Cloughesy T. F. Robins H. I. Dancey J. Prados M. D.; North American Brain Tumor Consortium. (2010). A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 12, 87–94.
19. Verhaak R. G. Hoadley K. A. Purdom E. Wang V. Qi Y. Wilkerson M. D. Miller C. R. Ding L. Golub T. Mesirov J. P. Alexe G. Lawrence M. O’Kelly M. Tamayo P. Weir B. A. Gabriel S. Winckler W. Gupta S. Jakkula L. Feiler H. S. Hodgson J. G. James C. D. Sarkaria J. N. Brennan C. Kahn A. Spellman P. T. Wilson R. K. Speed T. P. Gray J. W. Meyerson M. Getz G. Perou C. M. Hayes D. N. Cancer Genome Atlas Research Network. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17, 98–110.
20. Yan H. Bigner D. D. Velculescu V. Parsons D. W. (2009). Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. 69, 9157–59.